Quarterly report [Sections 13 or 15(d)]

Revenues from Contracts and Significant Customers (Tables)

v3.26.3
Revenues from Contracts and Significant Customers (Tables)
9 Months Ended
Sep. 30, 2026
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended September 30, 

​

Nine Months Ended September 30, 

($ in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Emrosi

​

$

9,002

​

$

4,883

​

$

23,329

​

$

9,748

Qbrexza

​

​

5,590

​

​

7,361

​

​

15,732

​

​

19,470

Accutane

​

​

3,023

​

​

2,769

​

​

9,694

​

​

9,818

Foam franchise products (Amzeeq & Zilxi)

​

​

942

​

​

1,311

​

​

2,933

​

​

3,973

Eurax

​

​

105

​

​

—

​

​

225

​

​

—

Other / legacy product revenue

​

​

263

​

​

701

​

​

772

​

​

2,164

Other revenue

​

​

234

​

​

606

​

​

1,229

​

 

2,010

Total net revenue

​

$

19,159

​

$

17,631

​

$

53,914

​

$

47,183